Hemostemix's Insider Lead Order of $330,000 Private Placement

Executive Summary

• Hemostemix announced a lead order of $330,000 for a non‑brokered private placement with total capacity up to $700,000.
• Units are priced at $0.11 each and consist of one common share plus one warrant exercisable at $0.15 per share for two years, with an acceleration feature tied to the market price.
• Proceeds will be used for general working capital, primarily to fund ongoing operational expenses and marketing/sales of the VesCell™ therapy.

Key Details

• Lead Order: $330,000 secured; total placement size up to $700,000.
• Unit Pricing: $0.11 per Unit.
• Unit Composition: 1 Common Share + 1 Warrant.
• Warrant Terms: Exercise price $0.15 per share; exercisable for two years from the Closing Date.
• Accelerator Clause: If, after four months + 1 day post‑closing, the closing sales price (or bid) exceeds a weighted average of $0.185 for any 10 consecutive trading days, Hemostemix may accelerate warrant expiry to 30 days after a press release notice.
• Related Party Transaction: A Director participates in the offering; exemption from formal valuation and minority shareholder approval relied upon under MI 61‑101 because neither fair market value exceeds 25% of market cap.
• Use of Proceeds: General working capital, including marketing and sales activities for VesCell™ (ACP‑01).

Notable Quotes

(No direct quotes were provided in the release.)